Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Logitech International SA — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Logitech International SA trades at $101.44 (market cap $14.53B). The key difference: Logitech International SA is the larger of the two by market cap, and Logitech International SA pays a 1.69% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LOGI | |
|---|---|---|
Market Cap | $8.04B | $14.53B |
Sector | Health | Technology |
52-Week High | $339.75 | $126.69 |
52-Week Low | $241.71 | $85.84 |
Enterprise Value | $7.85B | $12.88B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Logitech (LOGI) trades at $102.22, up 0.26% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a net margin of 14.69% and ROE of 32.78%, while recent quarters show consistent earnings beats. New product launches and a partnership with Call of Duty: Modern Warfare 4 highlight ongoing growth initiatives. Cash flow trends remain positive with 2026 operating cash flow projected at $1.0 billion.
Outlook is cautiously optimistic given mixed analyst ratings but solid fundamentals. Upside exists to the $113 consensus target, though competitive pressures and reliance on consumer spending pose risks. The stock offers value if execution on B2B and AI products drives margin expansion as anticipated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
